Approved by: _____
JSC Olpha Chairman of the Board
Juris Bundulis
Olaine, 07.08. 2025

Technical specification for the tender:
Development of Manufacturing Technology for a Final Dosage Form and Technology Transfer (ID 2025/08/8)

1. General information about the customer:

Name of customer: JSC Olpha
Commercial registration No.: 40003007246
Address: Rupnicu street 5, Olaine, LV-2114, Latvia
Contact persons:
Ēriks Ivanovskis, Director of Scientific Office, e-mail: Eriks.Ivanovskis@olpha.eu
Dita Siliņa, Project Manager, e-mail: Dita.Silina@olpha.eu
Kristīne Krūmiņa, Project Manager, Kristine.Krumina@olpha.eu

2. Procurement subject technical specification:

Development of manufacturing technology of a new pharmaceutical final dosage form and technology transfer to a site confirmed by Olpha. Product consists of two individual APIs. The final product must closely match the reference product in terms of appearance, physical attributes, and patient acceptability.
Additional information is available writing to the e-mail mentioned above.

Contractor shall provide Services according to EU pharmaceutical guidelines: European Pharmacopoeia general requirements, applicable ICH guidelines, EMA guidelines and SOW (available up on request).

Work to be performed		
1.	Job assignment	1. CQA Identification and IP clearance. 2. Active pharmaceutical ingredient. 3. Excipients. 4. Analytical methods for Finished Product. 5. Formulation development. 6. Technology transfer. 7. Dossier.
1.1.	CQA identification and IP clearance	1. CQA/CPP/CMA identification. 2. IP clearance report development.
1.2.	Active pharmaceutical ingredient	1. API sourcing according to EU GMP requirements (two individual APIs in one FDF that have at least one alternative). 2. Available Quality specification. 3. Each API source must be evaluated additionally for: • Polymorphic forms (if not described in ASMF);

		• Particle size (if not described in ASMF); • Data on polymorphism (XRPD) • Risk assessment on nitrosamines; • Risk assessment on mutagenic impurities; • Risk assessment on metals (Q3D); • Solubility in aqueous solution with phys.pH; • Compatibility studies; • Photostability data (if not described in ASMF); • Forced degradation studies (if not described in ASMF); • Impurity limits and justification, carry-over of impurities study; • Extractable/leachable declaration. 4. API data: pKa, log P/log D, pH solubility. Readiness to perform tests, if no data available. 5. Specification and test methods for API by drug product manufacturer. 6. Protocols for Analytical Method transfer for API (including PSD). 7. Analytical method validation/verification data for the method used for testing of API. 8. PDE/OEL report. 9. Declaration of Nitrosamine risk free/within limit from API suppliers.
1.3.	Excipients (only in case of new Excipient for Olpha)	1. Available analytical methods (or approbation from applicant). 2. Analytical methods validation according to ICH Q2(R1). 3. Available quality specification. 4. Analytical methods transfer (2 batches).
1.4.	Analytical methods for Finished Product (FP)	1. Available analytical methods for API and FP as per draft ICH Q14 and other applicable ICH guidelines. 2. Analytical methods validation according to ICH Q2(R1). 3. Available FP Quality specification (release and shelf life) and verification done according to ICH Q6A. 4. Justification of FP specifications. 5. Available discriminatory dissolution medium in line with EMA guidelines. 6. Available nitrosamine method.

		7. Available cleaning method and information about cleaning solvent for equipment cleaning. 8. FP forced degradation studies. 9. Specifications and analytical procedures for the routine proposed in-process controls in each step of the manufacturing process. 10. CoAs and characterization data for standards used for bacth analysis of drug product and method transfer. 11. Validation report for non-compendial methods. 12. Analytical methods transfer (2 batches).
1.5.	Formulation	1. Reference product analysis (physical and chemical including multimedia). 2. Reference product accelerated stability studies (6 months). 3. Manufacturing description including information about environmental condition required for manufacturing. 4. List of critical process parameters (control points) and their impact on CQA. 5. Bulk density of API, lubricated blend & core tablet for batch size calculation. 6. Drug-excipient compatibility studies. 7. Preliminary risk assessment for drug substance and formulation variables. 8. Prototype formulation development (at least 2 prototypes). 9. Stability on prototypes formulation at Zone II and Zone IVb conditions (6 months) based on ICH guidelines. 10. Stability on validation batch at Zone II and Zone IVb conditions (6 months) based on ICH guidelines. 11. Stability protocol for the exhibit batches. 12. Formula optimization report. 13. Process validation protocol for exhibit batches (signed); 14. Process validation report for exhibit batches (signed) 15. Drug excipient compatibility study report for he selected excipients. 16. TSE/BSE and Residual solvents statements from suppliers. 17. Declaration for compliance with guideline for residual solvents (ICH Q3C). 18. Specifications for excipients used for manufacturing. 19. If some specific excipients are used, at least one alternative should be given.

		20. Dissolution profiles in multimedia (at least 6 units). 21. Process optimization at lab scale. Indicate batch size. 22. Packaging material selection. 23. Certificate of analysis (from drug product manufacturer and from suppliers) of batches of primary packaging materials used in packaging of drug product exhibit batches. 24. Comparative IR spectra for each primary packaging material from all proposed suppliers. 25. Technical specifications of each primary packaging material from all proposed suppliers. 26. Compliance declaration (from all proposed suppliers) to relevant EU regulation (EU No. 10/2011 and all amendments) and any relevant Eur. Ph. Monographs.
1.6.	Technology transfer	1. Development of technology transfer protocols and reports. 2. Development of sampling, hold time, process evaluation protocols and reports. 3. Scale up/ feasibility batch manufacture (1 batch). 4. Scale up/ feasibility batch report development. 5. Manufacture of registration/ process validation batches (3 batches per strength). 6. Process validation protocol and report. 7. Final PDR. 8. Available Elemental & Nitrosamine risk assessment report.
1.7	Dossier	1. Provide full support in compiling Pharmaceutical (Section 3.2.P.2) part of eCTD. 2. Ensure the availability of the Dossier for submission in different regions. 3. Provide full support in addressing any regulatory queries during review/ approval of the dossier in the first country filed.

3. Requirements for Applicant

1.	Applicant's resources	Applicant has adequate scientific staff. Applicant must have necessary equipment to develop manufacturing technologies of new pharmaceutical final dosage forms.
2.	Final date of provision of services	Key milestones: AMT TT Successful BE study Dossier filing

		The final date of provision of services will be confirmed mutually with the chosen applicant. The conditions will be set in the contract. The final date of provision of services may be prolonged.
3.	Amount of work	Applicant shall apply for all activities presented in technical specification and SOW.
4.	Compliance	In case of possible equivalent for requirements listed in the description of procurement subject, unforeseen by the customer, the applicant can submit equivalent offer in conformity with requirements. The applicant can also submit the offer, which corresponds to higher (better) requirements.
5.	Price	Should be presented total amount of contract and separately for each specified activity according to section 1 "Job assignment", indicated in EUR (excluding VAT).
6.	Schedule of payment	The applicant agrees that the payment conditions will be set in the contract. The applicant can indicate the desired payment schedule in the application.
7.	Requirements the offer:	- Offer shall be submitted in accordance with the described in Procurement subject and SOW (available up on request); - Offer shall be written in English; - Indicate the date of preparation of the document, place and signature with a clarification, as well as the company's legal address and registration number; - The signed and scanned offer should be sent to: 1. Kristīne Krūmiņa, Project Manager, Procurement and Project Department, e-mail: kristine.krumina@olpha.eu; 2. Dita Siliņa, Project Manager, Scientific Office, e-mail: Dita.Silina@olpha.eu 3. Ēriks Ivanovskis, Director of Scientific Office, e-mail: Eriks.Ivanovskis@olpha.eu

4. Commercial terms

1.	Business model	*Please fill in the correct data* – Technology transfer + support / Co-development + Technology transfer + support
2.	Dosages	*Please check if all is available* - 24mg+26mg, 49mg+51mg, 97mg+103mg
3.	API or formulation – patent protection	*Please fill in the correct data* - Cocrystals / Separate API
4.	Country scope	*Please fill in the correct data* – Worldwide / EU27 + UK + CIS/EAEU / Pan-EU +UK + CIS/EAEU
5.	Dossier readiness status,	*Please fill in the correct data*

	Bioequivalence studies status	
6.	Co-development - cost	*Please fill in the correct data if it is applicable*
7.	Financial component – Dossier cost	*Please fill in the correct data if it is applicable*
8.	Technology transfer component - cost	*Please fill in the correct data if it is applicable*
9.	Technology transfer component - royalty	*Please fill in the correct data if it is applicable*
10.	API terms (cost, MOQ, in-house/not in-house)	*Please fill in the correct data if it is applicable*
11.	Additional terms – in case of sub-licensing	*Please fill in the correct data*
12.	Additional terms - On-site Technical support costs	*Please fill in the correct data*

This procurement is organized within the framework of project No. 5.1.1.2.i.0/1/22/A/CFLA/004.